2002•Journal watchRequires access
Tenecteplase Is More Effective with Enoxaparin than with Unfractionated Heparin
James M. Christenson, Frcpc
Open publisher page 0 citations
Abstract
The optimal pharmacologic regimen for patients with ST-elevation myocardial infarction (STEMI) is under debate. The GUSTO-V trial failed to demonstrate that the addition of abciximab to reteplase reduced mortality, whereas the ASSENT-3 trial demonstrated a reduction in combined death, MI, and recurrent ischemia when either abciximab or enoxaparin …